Andre Agassi is building a dyslexia assessment game

You probably know Andre Agassi from his incredible tennis career. But the former champion is making incredible moves in a totally different space – early childhood education and science. He’s not new to this space – he already has a foundation, the Andre Agassi Early Childhood Neuroscience Foundation, which he created to fund research and development of early literacy apps. And he is deeply involved in the education space in general – he’s helped build 70 charter schools in the past four years, educating 33,000 students.

For his latest project, Agassi announced at SXSW this year that his foundation is spearheading a dyslexia screening initiative. The initiative, called Readvolution, is focused on creating a dyslexia assessment game that will be completely free. Agassi’s foundation is partnering with neuroscientists from leading universities including California at San Francisco (UCSF) and the Weill Institute of for Neurosciences to formulate and scientifically validate the game.

Then, to actually build the game and provide further learning support, the foundation is partnering with Square Panda. Square Panda is an edtech startup that invented an AI-powered phonics-based system for early childhood reading and cognitive learning. They’ll use their AI to not only create the dyslexia assessment game, but also expand their educational offerings so that kids with dyslexia can acquire a broader range of language and literacy skills, too.

In an interview with Engadget, Agassi said he’s been using Square Panda’s offerings in his charter school in Las Vegas, and he immediately saw the difference it made in the students. “I’m very interested in this space,” Agassi said, “because I’ve seen first-hand what a challenge it can be to guide an entire classroom full of kids at the pace that each kid individually deserves.”

Why It’s Hot:
1: Collaborative teamwork across industries is an incredibly powerful tool.
2: Use your money and power for good, everyone!

Learn More: Engadget

British Airways expanding biometric gate screening in the US

British Airways is getting into the biometric game with its boarding gates in the US. Last year they began testing self-service boarding gates at LAX, and they are now rolling out the gates in some flights to/from Orlando, Miami, and JFK airports as well.

The new technology doesn’t replace security screenings; rather, it allows the airline to bypass scanning everyone’s boarding passes at the gate as they board the plane. Instead of having to produce their boarding pass, travelers just look into a camera, wait for their biometric data to scan and be confirmed against their passport/visa/immigration photos, and then proceed onto the plane. The main benefit? Speed. British Airways says that in LAX, these new gates allowed them to board 400 passengers in 22 minutes, less than half the time it usually takes.

Other airlines are getting in on the biometric tech too. JetBlue is trialing biometric boarding on flights from Boston to Aruba, and last year Delta started trying out facial recognition for checking luggage and fingerprints for boarding. Dubai International Airport is working on a tunnel equipped with both facial recognition cameras and iris scanners (!) that would cut the need for travel documents entirely.

Why It’s Hot: The impetus behind this tech development – faster, smoother boarding – is ostensibly a positive thing. But what databases are necessary for this kind of screening? Immigration and ID documents are incredibly sensitive, even more so in our current xenophobic political climate. Is cutting down boarding time worth the risk?

Learn More: Engadget | Forbes

Apple to open medical clinics for employees

Apple announced that it is opening medical clinics called “AC Wellness” for its employees (of which there are over 120,000). It quietly launched a website, for the venture that says:

AC Wellness is an independent medical practice dedicated to delivering compassionate, effective healthcare to the Apple employee population.

The company will build two clinics, one in the Apple headquarters building, and one just north of it. The clinics are going to be concierge-style, with job postings ranging from medical assistants / nurses / phlebotomists to primary care doctors, health partners, clinical exercise coaches, and care navigators. Sources told CNBC that Apple “plans to use AC Wellness clinics as a platform for testing out products and services that it could eventually provide for all consumers,” but it’s pretty clearly being rolled out as an employee-only venture for now.

Why It’s Hot: This isn’t the first instance of tech companies moving into the deeply dysfunctional healthcare space – Amazon recently announced a partnership with Warren Buffett and JPMorgan Chase, though the details of that partnership are sketchy. But this seems to be the first move by a tech giant to opening a privatized medical care center. In a country that already uses healthcare to stratify economic classes via linking insurance to jobs, what does it mean that Apple employees get not just better insurance, but better CARE because of their ability to get a job at Apple? What will happen if job-based doctor’s offices become the norm for certain social/economic classes of people?

Read More: Engadget | Gizmodo

Scientists develop a 3D-printed smartphone microscope

Australian researchers at the Centre of Excellence for Nanoscale BioPhotonics, a transdisciplinary government network, have created a 3D-printed device that clips onto smartphones, transforming them into fully functional microscopes. The device was developed with the goal of helping researchers and scientists have access to this crucial tool in remote regions and developing countries.

The microscope works by clipping an additional lens to the phone’s camera lens, and then holding slides up to it. Users can use the phone’s existing flash to do bright field or dark field imaging, which means the microscope can visualize both plant and mammalian cells. It’s powerful enough to view specimens as small as 1/200th of a millimeter. All of this means that the microscope can be used for things like analyzing water cleanliness, testing blood samples for parasites, and diagnosing diseases including malaria.

There are other portable microscopes on the market, but they require external LEDs and power sources, and get bulky surprisingly fast. This microscope makes full use of the smartphone as a power and light source, requiring nothing other than the clip itself.

Best of all? The researchers have made the 3D printing files free to the public. Good job, team.

Why It’s Hot: The 3D printer is again an innovation powerhouse, creating lifesaving technology with an incredibly low barrier to entry. And in making the printing files free to the public, these researchers are making a fantastic statement on putting the common good above individual profit. Would this have happened if a corporation, not a government program, made this innovation?

Learn More: Engadget | Newsweek

FDA Approves Blood Test That Can Detect Concussions

The FDA has approved the first-ever blood test that can detect signs of concussions, a huge step forward in the quest to make concussion diagnosis faster and more accurate.

The two main ways of detecting concussions now are giving patients a neurological test or, frequently, a CT scan. The neurological tests are not always accurate because the medical professional giving the test often isn’t familiar with the patient’s baseline performance. And CT scans, while a powerful diagnostic tool, expose people to high doses of radiation – about the equivalent of 100-200 chest X-rays – and are very expensive.

So it’s not that we don’t have ways of diagnosing concussions, it’s that our current method is akin to using a sledgehammer to pound a small nail. What’s missing is a way to figure out who should be given a CT scan for further diagnosis, and who doesn’t need it. This is where the blood test comes in.

The blood test works by measuring two proteins the brain releases into the blood after a head injury. The levels of these proteins will indicate whether the patient has lesions on their brain that will be visible in a CT scan or not. And it’s very accurate – it can predict the presence of a lesion 97.5% of the time, and determine who doesn’t have a lesion 99.6% of the time.

Though sports – football in particular – immediately come to mind (no pun intended) on the topic of concussions, the urgency of this drug development was actually a result of military necessity. As traumatic brain injuries have mounted during the wars in Iraq and Afghanistan, the armed forces have been desperately seeking a way to quickly predict whether a blow to the head has caused bleeding or bruising in the brain (and, therefore, what the best plan of treatment is). The development of this blood test, as well as the clinical trials preceding FDA approval, were largely underwritten by the U.S. Army Medical Research and Materiel Command. Test results can currently be obtained in 3-4 hours, but the Defense Department is working with the drug company to reduce that window to one hour.

Why It’s Hot: The funding and pressure from the armed forces had a huge impact on the speed of this blood test’s development and FDA approval. It will certainly benefit the men and women serving in the military, but it also has a massive wider impact on the general public, as well as other people at high risk for brain injuries (athletes, etc). What other medtech breakthroughs can we look forward to from unexpected sources?

Learn More: Engadget | LA Times


MDMA for PTSD enters final round of FDA trials

MDMA – aka ecstasy – as part of assisted psychotherapy is entering final round of clinical trials in Vancouver, clearing the path for Canada and the United States to approve the drug for therapeutic use as early as 2021. The therapy consists of three 8-hour sessions in which the participant takes MDMA, and 12 sessions without the drug. The entire process spans three-and-a-half months.

The FDA designated MDMA a “breakthrough therapy” for PTSD in August 2017, and they have agreed to approve the therapy if stage three studies show the drug is effective and there are no safety issues. They have also greenlit a third round of clinical trials in the US, but MAPS (the Multidisciplinary Association for Psychedelic Studies), the organization overseeing the research in North America needs to raise $25 million first to conduct the US study.

MDMA is an empathogen, meaning that it stimulates togetherness and trust among users. It also inhibits activity in the brain that treats fear and stimulates hormones that make people feel more connected. So the drug is powerful in PTSD therapy in particular because it allows participants to open up to their therapists and talk about their experiences in a trusting, bonded way.

Traditional PTSD treatments can last years and years, and focus on desensitization (aka reliving experiences) which can cause emotional pain and trauma. Just 10 to 15 percent of people recover, and the drop-out rate is high. MDMA-assisted therapy, on the other hand, usually lasts fewer than 4 months, and two-thirds of participants were free from PTSD one year after treatment.

“It wasn’t a party drug. There was no party. It wasn’t trippy. I didn’t see things. I didn’t have some miraculous spiritual experience. I didn’t get the urge to get up and dance. For the first time in years I was able to open up and talk painlessly. The fear, the barriers were removed and I was able to talk to these people.”
-Ed Thompson, former PTSD sufferer who participated in second-round trials

Why It’s Hot: The government has been incredibly slow to legalize psychedelics partly because, per MAPS founder Rick Doblin, pharmaceutical companies don’t stand to profit from studying compounds that are in the public domain and cannot be patented. This trial marks an important step toward legalization of a drug purely because of its therapeutic benefits, and not because of lobbying/fundraising/pressure from pharma companies.

Learn More: Newsweek | Globe & Mail 

FDA seeks to curb abuse of OTC anti-diarrhea meds via packaging

As a part of its efforts to curb the current opioid crisis in America, the FDA has requested that OTC anti-diarrhea medications modify its packaging to make overdosing more difficult.

These drugs, specifically Immodium A-D and various store brands and generics, are tied to the opioid crisis because in massive doses, the active ingredient, loperamide, works in the body the same way as heroin, morphine, and oxycodone. Some people suffering from addiction are buying the anti-diarrhea meds and consuming huge amounts of them – between 50 and 300 pills per day – in order to maintain their high or to self-treat their opioid withdrawal symptoms. Since the pills are relatively affordable, selling at big box stores at $10 for 400 pills, the drug is an appealing quick fix.

The FDA already added a warning to the product label in spring 2017 to warn against ingesting high doses of loperamide, including from abuse and misuse, but of course that warning label uh… didn’t help. (Shocker.) So they’re taking a design-based step and asking manufacturers to alter their physical packaging in order to change user behavior. For example, a retail package could contain eight 2-mg capsules, enough for two days of medication for its intended purposes. Think of how Sudafed, NyQuil, etc are packaged in individual and frustratingly difficult-to-open blister packs – it would take a lot of physical effort to gather and dose a huge quantity of those medications.

Why It’s Hot: Changing the physical packaging of medication to alter user behavior is a fascinating UX/product design strategy. It involves cost and effort on the manufacturer’s behalf to redesign and repackage the medication, but if it works, it’s a blunt and effective approach. What else could we physically alter in order to change users’ negative or self-harming behaviors?

Read More: CBS News | FDA

MIT Engineers Design Chip That Works Like Brain Synapses

MIT engineers have engineered a chip that mimics the human brain’s synapses, in a big development for the field of neuromorphic computing (aka computing that’s structured like neurons) and a step forward toward developing portable neural networks.

This chip is a big deal because human brains are, for now anyway, much more powerful than any computer. They contain 80 billion neurons, plus 100 trillion synapses that connect and control the flow of signals between the neurons. This vast network is remarkably hard to manifest in a computer chip because until neuromorphic computing, chips have always communicated in binary, with two signals: On and Off.

Brain synapses, however, can precisely control communication between neurons by adjusting their activation depending on the amount and kind of ions crossing the synapses. Essentially, communicating with chips is like painting in black and white (no mixing!), and communicating with brain synapses is like painting with an endless palette of colors.

Here’s a comparison: in 2013, a supercomputer using 83k processors and a petabyte of memory took 40 minutes to simulate one second of 1% of neural activity in a brain. (!!!)

The chip developed by the MIT engineers isn’t the first neuromorphic chip to be announced – Intel and IBM have tried to do so in the past, but their construction materials caused inconsistent synaptic activity, so the chips were unreliable. This MIT-created chip is using a new approach, designing the artificial synapses with a material called silicon germanium. This material allows for a precise control of the strength of the electrical current flowing between them, just as synapses can control the flow of ions between neurons. Unlike previous chips, this one thus far has proven to be incredibly reliable.

And the chip works: in a simulation, it recognized handwriting samples with 95% accuracy, compared to the 97% accuracy of existing software. The next step is to actually build a chip that is capable of carrying out the handwriting recognition task, with the end goal of creating portable neural network devices.

Why It’s Hot: Developing a chip that can successfully mimic synaptic communication would be a massive leap forward for the future of AI. Tasks and processes that we currently need supercomputers to execute would be possible to run from the phone in your pocket. The ramifications for medicine, science, and surely lots of goofy and sinister tech developments alike are endless.

Learn More: Engadget | Science Alert

New Digital Scale Won’t Tell You How Much You Weigh

Shapa is a new digital scale created by behavioral scientist Dan Ariely, a professor of behavioral economics at Duke University and author of many books including PREDICTABLY IRRATIONAL and THE (HONEST) TRUTH ABOUT DISHONESTY. His work looks into how humans make decisions, and the role of rationality – or irrationality – in our daily lives. He’s recently he’s turned his work to the decisions we make around health, and Shapa is one result of his work.

Shapa is unique in many ways, but the most obvious one is that it doesn’t have a screen and it won’t tell you how much you weigh. (Yep, a scale that doesn’t display weight.) This is a deliberate choice in today’s world of hypertracking. We have so many technologies at our fingertips that can track a million things about our bodies – from steps walked, flights of stairs climbed, hours slept, to muscle mass, water percentage, bone density, etc. And companies like Fitbit and Garmin even have smart scales, designed to work with their own wearables. Basically, more than ever, tech has enabled humans to create an entire ecosystem of data-driven knowledge about our own bodies.

The problem, Ariely says, is that the actual story of our health gets lost in these data points. “By giving people more granularity,” he says, “we’re making information less useful.” That’s especially true of weight, which can fluctuate as much as three pounds throughout the day. Watching the scale go up and down in normal, healthy patterns and scrutinizing it to a tenth of a pound tells us nothing about overall health.

Enter Shapa. With Shapa, the scale works in tandem with an app, so though the app is indeed recording your weight, it never tells you what that is. Instead, it displays a color, depending on if you’re underweight, about right or overweight, but nothing more specific. The app also sends you on goals and missions: things like tidy your bedroom, write a goal and affix it on your fridge, set an alarm on your phone to get up every two hours, walk to the gym, etc. Through these tasks and goals, the Shapa app is training you into better habits, and it’s also recording which habits are resulting in you making healthier decisions (as reflected in weight trends).

Why It’s Hot: This product, and the theory behind it, is taking the concept of the monitored human (and all the assorted tech developments) and turning it on its head. Is less information actually better when it comes to tracking your health? How can these psychology principles be applied to other health tracking fields?

Read More: Engadget | Wired

Samsung debuts smart glasses for people with vision impairments

Samsung announced this week that they will be debuting Relúmĭno, a VR-based smartphone app for people with vision impairments, at CES 2018. Relúmĭno is a product of their C-Lab (Creative Lab) program.

Jeonghun Cho, one of the C-Lab creators of Relúmĭno, said he was inspired to create these glasses after learning that only 14% of people with visual impairments are totally blind, and the remaining 86% of people have low vision and are typically able to distinguish between light and dark. He wanted to find a way to use technology to improve their residual vision, and from that goal, the Relúmĭno glasses were born.

One of the most significant aspects of these glasses is their price. Many products that improve visual perception are very expensive, so the Relúmĭno is significant in that it’s much more accessible from a price standpoint. Samsung achieved this by harnessing the power of the user’s smartphones and VR technology, so the only additional components that users need beyond a Samsung smartphone is a VR headset.

This product is still in its early stages, and their next hurdle will be completing a version of Relúmĭno that is fully housed within regular sunglasses, rather than the VR headset. This would make the product much more mobile, and would work better in outdoor conditions.

Why It’s Hot: Another incredible example of existing technology being used to bring life-changing quality of life improvements to people who really need it. What other significant medical problems can be solved with the tech we use every day?

Read more: Ars Technica | Samsung

Breakthrough Bacterial “Live Ink” Developed For 3D Printing

ETH Zurich, a science & tech university, has announced the development of a new kind of ink that contains live bacteria. This ink has fantastic implications for several areas of science, including cleaning up environmental pollution and creating medical supplies.

For environmental pollution, the ink is key because it suspends bacteria in a polymer hydrogel, which keeps the bacteria alive and fed for a time. Once the bacteria eat all of the hydrogel, it can begin to process other materials – for example, toxins in water. ETH Zurich researchers printed a live ink grid embedded with bacteria that eat the hazardous chemical phenol, and then put the lattice in phenol-contaminated water. The water was completely purified in just a few days.

For medical supplies, this ink is important not because of the bacteria itself, but because of the strands of material that the bacteria create when they move: bacterial cellulose. Bacterial cellulose is pure, holds a lot of water, and is soothing to wounds on human flesh. And it’s a natural material, so human bodies generally don’t reject the cellulose. As a result, this material is perfect for materials like skin transplants and wound dressings. Until now, bacterial cellulose could only be grown in flat sheets, which isn’t conducive to the contours of bodies – but now with this 3D ink, researchers can print cellulose in the shape of someone’s elbow, or face, or ankle, etc.

Why It’s Hot: There are SO many possible applications of this technology. 3D printing is relatively easy to access, and there are a million kinds of bacteria (unscientific estimation) that could be used and modified to achieve a multitude of goals. For example, researchers are already eyeing bacteria that could be genetically modified to secrete medicine to speed wound healing, and before you know it we’ll all be buying bacterially enhanced Band-Aids!

Read more: The Verge | Science News

This video game is also an ADHD prescription medicine

Akili Interactive just announced incredible results from a pivotal study of their investigational digital medicine, AKL-T01, aka a VIDEO GAME, in treating pediatric ADHD. This sounds bonkers but it’s true, I swear.

In a randomized, controlled trial of 348 kids and teenagers with ADHD, AKL-T01 showed a statistically significant improvement compared to an active control on the primary goal of changing the subjects’ Attention Performance Index, a measure of ADHD symptoms. With these study results in hand, Akili plans to file AKL-T01 with the FDA for clearance as a novel treatment for pediatric ADHD.

AKL-T01 is built on Akili’s proprietary Project: EVO tech platform that “enables selective targeting and activation of specific cognitive neural systems in the brain that exhibit deficiencies from various medical conditions” (BusinessWire). Basically, the game uses algorithms to deliver stimuli that engage targeted neural systems in the brain, and the algorithms automatically adjust the level, aka dose, of stimuli depending on the particular patient. The treatment looks and feels like a video game, with art, music, storytelling, and rewards to keep kids engaged for maximum compliance.

Why It’s Hot: IT’S A VIDEO GAME THAT IS ALSO A PRESCRIPTION FOR CHANGING NEURAL PATHWAYS IN PEOPLE. That is bonkers. If the FDA approves this as a medication, and the platform is expanded to treat other brain/neurological disorders, the possibilities are endless.

Learn More: BusinessWire | Reuters

Apple Watch Gains Momentum as Key AFib Diagnosis Tool

Two developments this week are putting Apple Watch front & center in the ongoing search for better atrial fibrillation (AFib) diagnostic and management tools. AFib is a condition where your heartbeat is irregular, and it often has zero symptoms and goes undiagnosed. It’s currently the leading cause of strokes, and related deaths and hospitalizations, in the US.

First, the FDA has cleared the first EKG band as a direct-to-consumer – meaning, you don’t need a prescription to purchase or use it – Apple Watch accessory. The KardiaBand, a device made by startup AliveCor, can capture your EKG in 30 seconds. The band’s algorithms can then detect whether signs of AFib are present in the EKG. The band also makes use of the Apple Watch’s heartbeat sensors and will alert you if your watch is picking up fast or irregular heartbeats, and prompt you to complete an EKG test on the spot to further analyze any symptoms you may be feeling.

Second, Stanford has launched an irregular heartbeat study using the Apple Watch and an app available on the App Store called Apple Heart Study. Users just download the app and consent to participate, and then their data is automatically collected and analyzed by Stanford. If AFib is detected, the app will send you a push notification as well as provide a free consultation with a Stanford doctor and an EKG patch for further monitoring. With Apple’s recent release of HealthKit and ResearchKit, this study is another step toward positioning the Apple Watch as a versatile, reliable health monitoring device.

Why It’s Hot: These two developments are cracking the facade of a time-honored medical tradition of keeping information about your own body behind expert oversight. The KardiaBand being direct-to-consumer indicates a big step forward in companies being able to build hardware and software that rival medical technology to a level that the FDA will approve it. And the Stanford study is working directly with Apple Watch users, not requiring any subjects to go into a medical facility for testing and data gathering. Is this the first step toward breaking down the expert oversight firewall? But of course, on the other hand, what are the ramifications of people’s health data being shared and stored on their devices?

Learn More: EKG band | Stanford study

FDA Approves First-Ever Digital Pill

The FDA has approved a pill called Abilify MyCite that can digitally track whether it’s been ingested, and when. The point of the medication is to increase patient compliance, the thought being that if the patient is being held accountable by their medication, they’ll be more likely to take their pills. Non-compliance is a huge issue – not only does it decrease patient outcomes, it’s also can create drug resistance, and in the case of overdosing, can create dangerous drug dependency.

The pill works via a sensor in the actual pill made of copper and magnesium that sends out an electric signal once the sensor hits the stomach acid. The patient wears a patch on their ribcage that receives the electric signal, and sends it along to an app that records the date and time of the pill digestion. The app allows for data sharing with doctors and family members (and sharing permissions can be revoked at any time).

Though the technology is promising, there are big ethical questions raised by this new pill. First, Abilify is an antipsychotic medication prescribed primarily to treat schizophrenia and bipolar disorder. The FDA’s approving of this particular kind of medication reflects a concerning disregard for the mental wellbeing of patients – Dr. Jeffrey Lieberman told The New York Times, “there’s an irony in it being giving to people with mental disorders that can include delusions. It’s like a biomedical Big Brother.” And his colleague Dr. Paul Appelbaum, Columbia’s director of law, ethics and psychiatry, pointed out that “drugs for almost any other condition would be a better place to start than a drug for schizophrenia.”

Second, the authority figures wielding this level of surveillance could easily manipulate patients. Imagine being told that your insurance company will cover 100% of your pill costs, but only if you take it on time every day. Or that you’re on parole and your freedom is contingent on taking medication. Or that your release from a psychiatric institution is predicated on your drug adherence.

Why It’s Hot: The technology itself is exciting – and the potential implications are fascinatingly broad, from improving patient outcomes to providing a whole new way for authorities to exert control over your physical being. (Yikes.)

Learn more: EngadgetNew York Times


EPA Approves Trial of Mosquitoes as Biopesticides

The EPA just approved the use of genetically engineered mosquitoes to fight mosquito-borne diseases. MosquitoMate, a biotech startup, has created mosquitoes with a modification that inhibits the reproductive cycle of mosquitoes in the wild. The goal is to introduce a natural (well, natural-ish) method of fighting diseases like Zika and dengue fever that are historically quite difficult to control, especially in zones where mosquito activity is high.

The GMO mosquitoes are given a bacterium to carry – Wolbachia pipienti – with the goal of spreading the bacterium to the wild populations of Asian tiger mosquitoes, the kind of mosquito that carries diseases. MosquitoMate breeds the infected bugs in their lab, and then separates the specimens into males and females. The males, who don’t bite, are released into treatment areas. When the GMO males mate with wild females, their eggs don’t hatch because of the bacterium (it prevents the paternal chromosome from forming correctly). Therefore, the mosquito circle of life is short-circuited after 30 to 40 days, the average lifespan of Asian tiger mosquitoes.

The EPA only okayed MosquitoMate to release their males into 20 states and DC, because those zones are most similar in climate to the three locations where the startup held its tests (KY, NY, and CA). MosquitoMate hopes to be able to iterate on their concept and create a different species that can be released all over the US.

Why It’s Hot: Not all biotech has to be complex or cutting-edge technologically. This startup, and the bacterium-carrying mosquito as biopesticide strategy overall, is pretty low-tech in terms of its mechanisms and functionality, but it has massive potential to improve public health and safety, not to mention general quality of life, for millions of people. Not everything has to be complicated in order to be groundbreaking!

Read More: Engadget | NatureMosquitoMate


Disney World Crowd Algorithms, Retrofitted for MedTech

Until recently, Len Testa used his computer science training to help people optimize their trips to Disney World through his algorithm-powered company Touring Plans. Now, he’s using his algorithms for something totally different: clinical diabetes decision-making software.

Recently approved by the FDA for clinical trial, GlucosePATH is an application that processes multiple data points and decides which medicine(s) their physicians should probably prescribe. GlucosePATH is significant because, in addition to processing medical data points, it incorporates the patient’s insurance data and factors financial considerations into its final decisions. (What good is a carefully chosen medicine if the patient can’t afford it anyway?)

The programming portion of building GlucosePATH was startlingly simple, says Testa. “There are around 6 million different combinations of diabetes medications to choose from in a typical office visit, but there are 2,432,902,008,176,640,000 different ways to visit 20 rides in a theme park. So the theme park problem is about 400 billion times bigger in terms of things that have to be considered.” Testa says he’s surprised that more medical decision-making isn’t automated; his work with GlucosePATH may just clear the way.

Why it’s hot: Tourism and medtech seem like they wouldn’t have much in common, but this teaming illustrates just how wrong that assumption is. This combination is a fantastic example of the possibilities of cross-pollenated ideas, no matter where they come from. What other solutions can we find by looking in unexpected places?

Learn more: MedGadget

Nordstrom Announces Small-Format, Brand-Focused Stores


Faced with diminishing profits in their brick-and-mortar business (along with the entire retail industry), Nordstrom announced a new, forward-thinking venture: Nordstrom Local, tiny stores with no inventory. This may seem counterintuitive, given Nordstrom’s historical dominance in the large-scale department store category, but the experimental stores are drawing on several key elements of recent commerce (and, specifically, e-commerce) successes like Warby Parker and Bonobos.

First, the stores are pivoting to a fully e-commerce process for purchasing items. These tiny stores will be outfitted (no pun intended) with devices that will allow customers to place orders for anything in the Nordstrom universe, and the stores will act as access points for customers wishing to pick up online orders and return items.

Second, the stores are also focusing on the brand experience, not the available inventory, as the core value-add of the physical location. Nordstrom Local stores will offer premium services such as personal stylists, wine, and manicures as a way to reframe the in-store experience as one of luxury, pampering, catered attention, etc.

Why it’s hot: With the retail industry in free-fall, retailers desperately need to innovate in order to survive, and these small-scale stores just might be the trick. Nordstrom isn’t the only one to try this approach – Sephora recently launched a similar small-scale store in Boston – but they’re certainly one of the largest. If their Local stores succeed, it may prove a path forward for other struggling retailers.

Read more: Fast Company | Bloomberg

LAPD Gets Green Light For a Drone Pilot Program

The LAPD got the go-ahead this week from a civilian oversight panel to roll out a year-long drone pilot program. The panel voted 3-1 on this contentious issue, and the city is set to start using two drones within the next 30 days. The LAPD is the nation’s largest police force, so the implications for this development are huge.

Advocates for the drone program say it will protect officers and civilians by using drones instead of humans to gather crucial information in dangerous situations (active shooters, hostage situations, search & rescue missions, etc). The pilot program comes with strict rules on when the drones may be used – only with SWAT team members in the aforementioned dangerous situations – and every flight must be approved, documented, and reviewed. There’s a ban on facial recognition software and drone-operated weapons, and the Police Commission with publish quarterly reports on all drone activity.

Even with these restrictions in place, the program is facing heavy criticism from the public, as well as civil liberty and privacy organizations (the ACLU of Southern California and the Stop LAPD Spying Coalition sent letters to the LAPD urging them to kill the pilot program). The outcry all comes down to one thing: Trust. The LAPD has a contentious history with regard to technology implementation, most prominently in its rollout of body cameras without a policy in place to release the footage to the public. Jim Lafferty, the executive director emeritus of the National Lawyers Guild Los Angeles, says:

“Mission creep is of course the concern. . . . The history of this department is of starting off with supposedly good intentions about the new toys that it gets . . . only to then get too tempted by what they can do with those toys.”

Los Angeles isn’t the first city to attempt to use drones as a part of their police forces – and this isn’t even the first time the LAPD has tried to use drones. Seattle tried to start up a police drone program in 2013, but after heavy criticism from the public, the city killed the program and sent their drones to Los Angeles. The public outcry followed the drones to LA, and the LAPD also grounded and ultimately destroyed the drones without ever using them.

So why, a few years later, are they reviving and pushing forward with this program? Charlie Beck, the LAPD police chief, said at the panel vote meeting that more agencies are using drones, and there’s a “much more robust feedback mechanism” in place now. Time will tell whether these factors have any influence on keeping the drone program within their stated bounds.

Why it’s hot (and/or terrifying, depending on your view): The LAPD is the nation’s largest police force, and the outcomes of this pilot program will have a significant impact on future developments in unmanned civilian surveillance by our own government.

LA Times | Engadget

Tamagotchis are back!

[insert siren emoji here] Big news: Bandai just released a new line of Tamagotchis to celebrate the iconic toy’s 20th anniversary! These little buddies are very similar to their original predecessors, 256-pixel screen and all – the only real difference is that they’re about 20% smaller than the classic version. There are six shell designs to choose from, and the digital pets are just as needy and adorable as you remember them being. Have fun!

Why it’s hot: The trend of reviving 90s-era tech & toys continues! Nokia re-released its classic 3310 mobile phone earlier this year, and Nintendo released a NES Classic Edition last year. Is Game Boy next??!!

Read more: Gizmodo | Engadget

Biotech startup Taxa debuts genetically engineered fragrant moss

Taxa, a biotech startup in Silicon Valley, has debuted a new product: Orbella, a line of three fragrant mosses genetically engineered to give off aromas of patchouli, linalool (floral, clean, and fresh), and geraniol (rose-like). The project is a textbook example of synthetic biology, or synbio, which is the application of engineering techniques to the building blocks of life. (Basically, creating new life forms.)

Orbella was produced through a collaboration between Taxa and Dr. Henrik Simonsen, a professor at the University of Copenhagen whose work focuses on using photosynthesis (as opposed to conventional chemical synthesis) to biosynthesize small molecules.

The scented mosses were created by taking genes associated with a certain scent and splicing them into the moss genes. The actual process sounds like a near-future sci fi plot point: the scientists design the spliced gene online, use a gene gun (real name) to insert the genes into the moss cells, and then grow the GMO moss in liquid form.

If you’ve heard of Taxa before, it’s probably because of their intensely controversial Glowing Plant Kickstarter project. Back in 2013, Taxa successfully funded the Glowing Plant project with the promise of delivering a genetically modified plant that’d glow in the dark. Problem is, the biotech required to actually produce the glowing plant proved to be beyond Taxa’s reach, and their actual product hardly emitted any light.

Regardless of the success (or not) of the Glowing Plant itself, the Kickstarter project faced heavy blowback amid concerns of GMO products hitting consumer markets without any regulatory oversight. Prompted by the Glowing Plant controversy, Kickstarter banned GMO projects shortly thereafter. Taxa then pivoted to fragrant moss, which is much easier to engineer due to its simpler genome and shorter life-cycle, which allows scientists to run experiments more quickly.

Why It’s Hot: Orbella is a step forward in the consumer-facing biotech sphere. Taxa’s hope is that the product helps to positively change people’s perception of GMOs and demonstrate the varied uses of the emerging technology. Taxa is also funded primarily through crowd funding, and they’re an independent biotech company – their work is proving that GMO products don’t have to be the sole purview of massive conglomerates.

More significantly, though, the synbio field is truly the future of biotech, and represents mind-bogglingly vast possibilities for humanity – along with equally vast moral and ethical quandaries. How much modification is too much? Where’s the line between a fun, harmless GMO like scented moss and something more troubling? And who should be allowed to produce, and sell, and purchase GMO products in the first place?

Orbella Moss: Gizmodo | Business InsiderOrbella Moss
The Glowing Plant project: Kickstarter | Mother Jones | The Verge

Assassin’s Creed Origins Releasing Zero-Combat Mode

Ubisoft announced the development of a zero-combat mode for Assassin’s Creed Origins, the soon-to-be-published tenth installment of the wildly popular Assassin’s Creed series of video games. While Assassin’s Creed games typically involve a hefty dose of violence along with their sprawling, historically accurate worldbuilding, the zero-combat mode will turn Ubisoft’s massive re-creation of Ancient Egypt into an interactive, living historical world.

The educational mode will feature dozens of guided tours that focus on subjects like the Great Pyramids, mummification, and the life of Cleopatra, among others. Players can also simply roam through the entire world without having to keep looking over their (virtual) shoulders, taking time to wander and explore the vast landscape that includes Alexandria, the Sand Sea, the Giza Plateau, and more.

The content is painstakingly vetted to ensure historical and cultural accuracy, thanks to the team of historians and Egyptologists who helped create the educational world. According to Jean Guesdon, the creative director for Assassin’s Creed Origins, “We spent years recreating Ancient Egypt, documenting ourselves, validating the content with historians, with consultants, and we feel that many more people than just the players can benefit from that.”

The update doesn’t land until 2018, but when it’s ready, it’ll be a free upgrade for everyone who’s already purchased the game.

Why it’s hot: The zero-combat mode is a significant play for Ubisoft, who may be trying to get into the education space with this release. Guesdon says, “I hope that teachers will seize this opportunity to present that to their students, so they can learn with this interactive medium.” Regardless of their broader intention, it represents an exciting (and fun!) new application of the Assassin’s Creed series’ worldbuilding technology and expertise.

Ubisoft blog | Engadget | Ars Technica

Record-setting EV announced – and it’s a dump truck

A new experimental electric vehicle project is underway in Switzerland, and its sheer power puts Tesla to shame.

A Komatsu quarry truck, a massive vehicle whose wheels are the size of an adult human, is being modified by Kuhn Schweiz (a Swiss construction machinery company) and Lithium Storage (a European lithium battery supplier) to run entirely on electric power. The truck weighs 45 tons when empty, can carry an additional 65 tons of material, and is powered by a 700kWh battery pack – the equivalent of 8 Tesla Model S batteries.

The Komatsu’s regenerative braking technology is the key to its energy surplus. Because the truck carries such heavy loads, it generates more electricity driving (and braking) downhill on the way to the quarry than it needs to get back up the hill. The extra energy generated – approximately 10kWh per trip uphill, and it makes approximately 20 trips per day – feeds directly back into the local energy grid.

Why it’s hot:
The sheer size of the Komatsu, and the surplus of electricity it generates, is a significant, concrete (no pun intended) step in the expansion of electric vehicle technology beyond personal cars. Transitioning heavy machinery and commercial modes of transportation to electric power will have a massive impact on air quality, emissions, and global fossil fuel consumption.


Why it’s not super hot quite yet:
The Komatsu is still in development, and there are questions still being researched about the longevity and functionality of the battery under harsh construction environments.

Learn more: